



## Medica Central Coverage Policy

**Policy Name:** Non-pneumatic Compression Systems or Garments (e.g., Dayspring)  
MP9750

**Effective Date:** 06/01/2024

### Important Information – Please Read Before Using This Policy

These services may or may not be covered by all Medica Central plans. Coverage is subject to requirements in applicable federal or state laws. Please refer to the member's plan document for other specific coverage information. If there is a difference between this general information and the member's plan document, the member's plan document will be used to determine coverage. With respect to Medicare, Medicaid, and other government programs, this policy will apply unless these programs require different coverage.

Members may contact Medica Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions may call the Provider Service Center. Please use the Quick Reference Guide on the Provider Communications page for the appropriate phone number. <https://mo-central.medica.com/Providers/SSM-employee-health-plan-for-IL-MO-OK-providers>

Medica Central coverage policies are not medical advice. Members should consult with appropriate health care providers to obtain needed medical advice, care, and treatment.

### Coverage Policy

Non-Pneumatic Compression Systems or Garments (e.g., Dayspring) is considered investigative and unproven and therefore **NOT COVERED**. There is insufficient reliable evidence in the form of high quality peer-reviewed medical literature to establish the efficacy or effects on health care outcomes.

**Note:** see also related coverage policies *Liposuction for Lymphedema or Lipedema*, *Bioimpedance Spectroscopy (BIS)* and *Bioelectrical Impedance Analysis (BIA) for Detection of Lymphedema*.

### Description

A non-pneumatic Compression System or Garment (e.g., Koya Dayspring System) is a wearable compression device that uses sequential gradient compression for the treatment and management of patients with lymphedema and provides patients with mobility during treatment. The Koya Dayspring system is also indicated for the treatment of venous insufficiency and promotion of wound healing.

The Koya Dayspring® consists of a programmable, segmental controller with a sleeve garment that can be sized to fit the individual. The garment contains a shape memory alloy made with nickel/titanium (Ni-Ti) that is programmed by a rechargeable controller to shrink in a cyclic manner, applying active gradient pressure from the distal to proximal end of the limb. This mechanistic action is similar to the motion of advanced pneumatic compression devices and is purported to provide comparable compression to existing pneumatic pumps via segments that contract and relax flexible frames in a segmental appliance without the use of air. Up to 14 independently controlled segments can be programmed to deliver 0–100 mmHg of compression



## Medica Central Coverage Policy

pressure, with typical initial settings in a range of 30–40 mmHg. A mobile phone application can be used to program and individualize pressures; to start, stop, and pause therapy; and to track device usage. The function of the device allows for mobility and range of motion during treatment. According to the manufacturer, the device is built on Flexframe2 technology, a patented mobile platform that provides calibrated sequential gradient.

### FDA Approval

- In September 2021, the Dayspring Lite device obtained U.S. Food and Drug Administration (FDA) approval via the 510(k)-approval process as a compressible limb sleeve (K212287). Dayspring Lite is a prescription only wearable compression system, intended for use in a clinic or home setting by medical professionals and patients who are under medical supervision. FDA indications include the following conditions:
  - Chronic edema
  - Lymphedema
  - Venous insufficiency
  - Wound healing.

Dayspring Lite is developed on a wearable compression technology platform, which is designed to provide mobility for patients.

- On April 23, 2021, the Koya Dayspring system obtained FDA approval via the 510(k)-approval process as a wearable compression system (K210885). Koya Dayspring system is a prescription only wearable compression system, intended for use in a clinic or home setting by medical professionals and patients who are under medical supervision to increase lymphatic flow in the treatment of or various conditions such as:
  - Lymphedema
  - Primary lymphedema
  - Post mastectomy edema
  - Edema following trauma and sports injuries
  - Post immobilization edema
  - Venous insufficiency
  - Reducing wound healing time
  - Treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers
  - Lipedema
  - Phlebolympedema

The Dayspring system is developed on a wearable compression technology.

### Prior Authorization

Prior authorization is not applicable. Claims for this service are subject to retrospective review and denial of coverage, as investigative services are not eligible for reimbursement.

### Coding Considerations

Use the current applicable CPT/HCPCS code(s). The following codes are included below for informational purposes only, and are subject to change without notice. Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement.



## Medica Central Coverage Policy

### CPT Codes

- **E0677** – Nonpneumatic sequential compression garment, trunk
- **E0678** – Nonpneumatic sequential compression garment, full leg
- **E0679** - Nonpneumatic sequential compression garment, half leg
- **E0680** - Nonpneumatic compression controller with sequential calibrated gradient pressure
- **E0681** - Nonpneumatic compression controller without calibrated gradient pressure
- **E0682** - Nonpneumatic sequential compression garment, full arm

	Committee/Source	Date(s)
<b>Document Created:</b>	Medical Policy Committee/Health Services Division	January 17, 2024
<b>Revised:</b>	Medical Policy Committee/Health Services Division	May 15, 2024
<b>Reviewed:</b>	Medical Policy Committee/Health Services Division	May 15, 2024

Published: 06/01/2024

Effective: 06/01/2024

© 2024 Medica.